Semaglutide Explained: Structure and glucagon-like peptide-1 (GLP-1) Receptor Signaling

What does GLP-1 receptor agonist mean?

GLP-1 stands for glucagon-like peptide-1, a naturally occurring peptide signal. Its receptor, abbreviated glucagon-like peptide-1 receptor (GLP-1R), is a protein that receives that signal. Semaglutide is an analogue: a molecule with a related but modified structure. It is also an agonist, meaning it can bind to the receptor and promote its activation. [1] [2]

“Analogue” describes a structural relationship. “Agonist” describes activity at a target. Keeping the terms separate helps when reading a paper: chemical resemblance and a measured receptor response are different pieces of evidence.

Follow the signal into the cell

GLP-1R belongs to the G protein-coupled receptor family. It spans the cell membrane, connecting an interaction outside the cell to signaling machinery inside. A structural study has captured semaglutide bound to GLP-1R together with the stimulatory G protein, Gs. [2] [3]

One downstream messenger is cyclic adenosine monophosphate (cAMP). It carries a signal within the cell and can change the activity of other proteins. A cAMP measurement therefore tells researchers about one part of the response. [4]

Explore the signaling pathway in more detail

An activated receptor can engage Gs. Gs then stimulates adenylyl cyclase, an enzyme that converts adenosine triphosphate (ATP) into cAMP. One target of cAMP is protein kinase A (PKA), which adds phosphate groups to other proteins and can alter their activity. [4]

The receptor, G protein, enzyme and messenger perform different jobs. An arrow in this simplified pathway means that one step influences the next; it does not mean that the peptide travels through every step.

What semaglutide is made of

Semaglutide has a backbone of 31 amino-acid residues: building blocks joined in a particular order by peptide bonds. A chemical branch attaches to a lysine side chain. [1] [5]

The branch contains a linker and an 18-carbon fatty diacid. It is attached to the backbone; it is not an extra stretch of the 31-residue sequence. A sequence listing and a complete chemical structure therefore show different amounts of information. [1]

Why a paper says position 26 in a 31-residue peptide

Semaglutide is based on the GLP-1(7–37) sequence. Papers often preserve those GLP-1 positions, while a simple count along the chain runs from 1 to 31. [5] [6]

Subtract six to translate the conventional GLP-1 position into a position within this chain: Aib8 becomes residue 2, Lys26 becomes residue 20, and Arg34 becomes residue 28. Check the numbering convention before comparing a sequence, diagram or methods section.

Albumin binding answers a different question

Semaglutide’s lipid modification supports reversible binding to albumin, a soluble protein. Albumin binding can influence the peptide available to interact with receptors in an assay. [7]

Before comparing results, identify what was measured. Binding, signaling and structure can complement one another, but each needs its own experiment.

Read one semaglutide experiment

Find semaglutide in Table 3 of Lau and colleagues’ discovery paper. The binding assays used membranes from baby hamster kidney (BHK) cells expressing GLP-1R. [7]

The semaglutide binding half-maximal inhibitory concentration (IC50) is larger at 2% albumin. The table’s nominal 0% condition needs a methods check: it actually contained 0.005% albumin. [7]

Open Table 3 in the original paper (Portable Document Format (PDF), page 5)

Practice evaluating models, measurements and study conclusions →

See how semaglutide fits the receptor

Open entry 7KI0 in the Research Collaboratory for Structural Bioinformatics (RCSB) Protein Data Bank (PDB). Its cryogenic electron microscopy (cryo-EM) model contains semaglutide, GLP-1R and Gs. Locate the peptide chain and the much larger receptor around it. [3]

Zhang and colleagues found the peptide’s amino end deep in the receptor’s membrane-spanning region, while its other end contacts the extracellular domain. Only part of the lipid-bearing branch could be modeled: the complete fatty diacid was not resolved. A missing segment in a structural model does not mean it was absent from the molecule studied. [6]

This distinction is useful beyond semaglutide. Read a structure as an experimentally supported model with limits. Pair it with functional measurements when the question concerns activity.

Explore the semaglutide–GLP-1R–Gs structure in RCSB PDB

Keep the conclusion tied to the experiment

For any semaglutide paper, write down the molecule tested, the experimental model, the comparison and the measured response. That turns a broad claim such as “it binds better” into a statement someone else can check.

The studies discussed here examine molecular structure and laboratory responses. They do not establish effects in people or verify the identity, purity, composition or biological activity of a particular Freedom Peptides lot.

Compare all three: semaglutide, tirzepatide and retatrutide →